Clinical Trial

68Ga-AAZTA-NI-093 PET/CT: First-in-human Study

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated September 25, 2024 (before its estimated August 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
68Ga-AAZTA-093 is a novel radiotracer incorporating a hypoxia sensitive nitroimidazole(NI)-moiety and a PSMA-targeting. In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of 68Ga-AAZTA-NI-093 PET/CT in patients with prostate cancer.
Trial Details
NCT Number NCT06612580
Lead Sponsor First Affiliated Hospital of Fujian Medical University
Conditions Prostate Cancer (Adenocarcinoma)
Enrollment 10 participants
Start Date 2024-09-01
Primary Completion 2025-08-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-09-25